NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02314819,A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients ï¼ˆFRESCO),https://clinicaltrials.gov/study/NCT02314819,FRESCO,COMPLETED,Fruquintinib administered at 5mg once daily(QD) in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with metastatic colorectal cancer (CRC) in phase Ib and phase 2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of patients with metastatic CRC who have progressed after second line or above standard chemotherapy,NO,Colorectal Cancer,DRUG: fruquintinib|DRUG: placebo,"overall survival, every two months after end of treatment (EOT) observation period at 30 days after the last medication, from randomization until death due to any cause, assessed up to 2 year","progression free survival, Tumor assessment will be performed using radiography method every 8 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year|Objective Response Rate (ORR), Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year|Disease Control Rate (DCR), Tumor assessment will be performed using radiography method every 8 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year|Safety and tolerance evaluated by incidence, severity and outcomes of AEs, Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 4.0., from first dose to within 30 days after the last dose",,Hutchison Medipharma Limited,Fudan University|Eighty-One Hospital of People's Liberation Army,ALL,"ADULT, OLDER_ADULT",PHASE3,416,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-013-00CH1,2014-12,2017-01,2017-01-17,2014-12-11,,2020-02-17,"Hutchison Medi Pharma Investigational Site, Hefei, Anhui, 230000, China|Hutchison Medi pharma Investigational Site, Beijing, Beijing, 100071, China|Hutchison Medi Pharma Investigational Site, Guangzhou, Guangdong, 510000, China|Hutchison Medi Pharma investigational site, Shenzhen, Guangdong, 518036, China|Hutchison Medi Pharma Investigational Site, Liuzhou, Guangxi, 545005, China|Hutchison Medi Pharma Investigational Site, Harbin, Heilongjiang, 150081, China|Hutchison Medi Pharma Investigational Site, Changsha, Hunan, 410013, China|Hutchison Medi Pharma Investigational Site, Changzhou, Jiangsu, 213000, China|Hutchison Medi Pharma Investigational Site, Nanjing, Jiangsu, 210000, China|Hutchison Medi Pharma Investigational Site, Nantong, Jiangsu, 226000, China|Hutchison Medi Pharma Investigational Site, Xuzhou, Jiangsu, 221000, China|Hutchison Medi Pharma Investigational Site, Changchun, Jilin, 130000, China|Hutchison Medi Pharma Investigational Site, Qingdao, Shandong, 266000, China|Hutchison Medi Pharma Investigational Site, Shanghai, Shanghai, 200032, China|Hutchison Medi Pharma Investigational Site, Hangzhou, Zhejiang, 310000, China",
